Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT

Incannex Healthcare Inc.

Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.
Analyst James Molloy, AGP Managing Director and Senior Biotechnology Analyst, authored the report.
Incannex's lead programs: IHL-42X for obstructive sleep apnoea (DReAMzz study) and PSX-001 synthetic psilocybin for generalized anxiety disorder.
AGP has received compensation from Incannex for providing investment banking services.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.